Can-Fite Updates Namodenoson Patent

Can-Fite BioPharma Ltd., a leading biotechnology firm, has provided an update on the intellectual property status of its main drug candidate, Namodenoson. This drug is being developed to treat advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis (MASH). The patents and applications cover treatment methods for liver and pancreatic cancers using Namodenoson in an oral formulation and for improving liver steatosis, inflammation, and fibrosis in MASH. A recent patent application has been filed to protect the drug's manufacturing process. The granted patents and pending applications are expected to provide protection until at least 2044.

The company has multiple granted patents and corresponding applications in various regions, including Europe and the United States. Can-Fite's Chief Scientific Officer and Chairperson, Dr. Pnina Fishman, expressed satisfaction with the broad protection that Namodenoson has in oncology and MASH. The company aims to expand this protection to additional geographies.

Currently, Can-Fite is conducting significant clinical trials for Namodenoson. These include a Phase III trial for advanced liver cancer and a Phase IIb trial for MASH, both conducted in agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Namodenoson is an orally bioavailable drug that binds with high specificity and affinity to the A3 adenosine receptor (A3AR). This receptor is predominantly expressed in diseased cells, which helps explain the excellent safety profile of the drug. The company is also planning a Phase IIa study to explore Namodenoson’s potential in treating pancreatic cancer.

Can-Fite BioPharma Ltd. is an advanced clinical-stage drug development company focused on creating treatments for cancer, liver, and inflammatory diseases. Apart from Namodenoson, the company’s lead drug candidate, Piclidenoson, recently completed a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Namodenoson, which has shown potential in treating other cancers such as colon, prostate, and melanoma, has been granted Orphan Drug Designation in the U.S. and Europe. Additionally, it has received Fast Track Designation for use as a second-line treatment for hepatocellular carcinoma (HCC) by the FDA.

Namodenoson has demonstrated proof of concept in potentially treating other cancers, including colon, prostate, and melanoma. The company's third drug candidate, CF602, has shown efficacy in treating erectile dysfunction. In total, these drugs have an excellent safety profile, with over 1,600 patients having participated in clinical studies to date.

Can-Fite BioPharma continues to push the boundaries in the treatment of serious diseases with its innovative drug pipeline, aiming to bring new and effective treatments to market while ensuring a broad scope of intellectual property protection.